Company: MBIO
Filing Date: 2025-02-27
Form Type: 424B3
Source: 0001104659-25-018303
Chunk: 19

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-27
Form: 424B3
Chunk 19
---
 of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. The Company’s forward-looking statements, include, but are not limited to, any statements relating to our growth strategy and product development programs, including the timing of and our ability to make regulatory filings such as INDs and other applications and to obtain regulatory approvals for our product candidates, statements concerning the potential of therapies and product candidates and any other statements that are not historical facts. Actual events or results may differ materially from those described in this press release due to a number of risks and uncertainties. Risks and uncertainties include, among other things,our need for substantial additional funds in the immediate future; risks that
any actual or potential clinical trials may not initiate or complete in sufficient timeframes to advance the Company’s corporate
objectives, or at all, or that any promising early results obtained therefrom may not be replicable; risks related to the satisfaction
of the conditions necessary to transfer the lease of the Company’s manufacturing facility; disruption from the sale of the Company’s
manufacturing facility making it more difficult to maintain business and operational relationships; negative effects of Company announcements
on the market price of the Company’s common stock; the development stage of the Company’s primary product candidates; our
ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of
research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to
preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel;
the early stage of products under development; government regulation; patent and intellectual property matters; competition; as well as
other risks described in Part I, Item 1A, “Risk Factors,” in our Annual Report on Form 10-K filed on March 11,
2024, subsequent Quarterly Reports on Form 10-Q, and our other filings we make with the SEC. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in
our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required